2024 FDA Developments Several important FAA and FDA actions occurred in 2024: In January 2024, tirzepatide (Zepbound, Mounjanaro) was added to the FAAs Conditionally Acceptable Weight Loss Medications category, but medical certification required Special Issuance
This method facilitates immediate absorption, offering effective results by bypassing the digestive system
While this is not well established, monitoring for a lump in the neck, hoarseness, difficulty swallowing, or shortness of breath is advised
Busetto L, Dicker D, Frhbeck G, et al
For women with PCOS, a slow metabolism can make weight management particularly difficult
Enrichment and isolation of DEHP-degrading bacteria In this study, six soil samples from an electronics factory were collected and stored at 4 C for one week prior to mixing and use